A citation-based method for searching scientific literature

Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara, Junko Yamaguchi, Chiaki Ishii, Naoya Harada, Masako Soma, Hiromi Okamoto, Masataka Oitate, Shingo Arakawa, Takehiro Hirai, Ryo Atsumi, Takashi Nakada, Ichiro Hayakawa, Yuki Abe, Toshinori Agatsuma. Clin Cancer Res 2016
Times Cited: 263







List of co-cited articles
1132 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Shanu Modi, Cristina Saura, Toshinari Yamashita, Yeon Hee Park, Sung-Bae Kim, Kenji Tamura, Fabrice Andre, Hiroji Iwata, Yoshinori Ito, Junji Tsurutani,[...]. N Engl J Med 2020
456
51


Trastuzumab emtansine for HER2-positive advanced breast cancer.
Sunil Verma, David Miles, Luca Gianni, Ian E Krop, Manfred Welslau, José Baselga, Mark Pegram, Do-Youn Oh, Véronique Diéras, Ellie Guardino,[...]. N Engl J Med 2012
36

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Kohei Shitara, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun-Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee,[...]. N Engl J Med 2020
212
30

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Toshihiko Doi, Kohei Shitara, Yoichi Naito, Akihiko Shimomura, Yasuhiro Fujiwara, Kan Yonemori, Chikako Shimizu, Tatsunori Shimoi, Yasutoshi Kuboki, Nobuaki Matsubara,[...]. Lancet Oncol 2017
164
29

Strategies and challenges for the next generation of antibody-drug conjugates.
Alain Beck, Liliane Goetsch, Charles Dumontet, Nathalie Corvaïa. Nat Rev Drug Discov 2017
917
26

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
25

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Shanu Modi, Haeseong Park, Rashmi K Murthy, Hiroji Iwata, Kenji Tamura, Junji Tsurutani, Alvaro Moreno-Aspitia, Toshihiko Doi, Yasuaki Sagara, Charles Redfern,[...]. J Clin Oncol 2020
131
25

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Gail D Lewis Phillips, Guangmin Li, Debra L Dugger, Lisa M Crocker, Kathryn L Parsons, Elaine Mai, Walter A Blättler, John M Lambert, Ravi V J Chari, Robert J Lutz,[...]. Cancer Res 2008
24

The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
Takashi Nakada, Kiyoshi Sugihara, Takahiro Jikoh, Yuki Abe, Toshinori Agatsuma. Chem Pharm Bull (Tokyo) 2019
90
23

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Kenji Tamura, Junji Tsurutani, Shunji Takahashi, Hiroji Iwata, Ian E Krop, Charles Redfern, Yasuaki Sagara, Toshihiko Doi, Haeseong Park, Rashmi K Murthy,[...]. Lancet Oncol 2019
123
20

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Kohei Shitara, Hiroji Iwata, Shunji Takahashi, Kenji Tamura, Haeseong Park, Shanu Modi, Junji Tsurutani, Shigenori Kadowaki, Kensei Yamaguchi, Satoru Iwasa,[...]. Lancet Oncol 2019
89
21

A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model.
Tomomi Nakayama Iwata, Chiaki Ishii, Saori Ishida, Yusuke Ogitani, Teiji Wada, Toshinori Agatsuma. Mol Cancer Ther 2018
69
26

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, S G Wong, W J Levin, A Ullrich, W L McGuire. Science 1987
16

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, T Fleming, W Eiermann, J Wolter, M Pegram,[...]. N Engl J Med 2001
16

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
14


Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.
Kevin J Hamblett, Peter D Senter, Dana F Chace, Michael M C Sun, Joel Lenox, Charles G Cerveny, Kim M Kissler, Starr X Bernhardt, Anastasia K Kopcha, Roger F Zabinski,[...]. Clin Cancer Res 2004
712
13

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Ian E Krop, Sung-Bae Kim, Antonio Gonzalez Martin, Patricia M LoRusso, Jean-Marc Ferrero, Tanja Badovinac-Crnjevic, Silke Hoersch, Melanie Smitt, Hans Wildiers. Lancet Oncol 2017
220
13

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Aditya Bardia, Ingrid A Mayer, Linda T Vahdat, Sara M Tolaney, Steven J Isakoff, Jennifer R Diamond, Joyce O'Shaughnessy, Rebecca L Moroose, Alessandro D Santin, Vandana G Abramson,[...]. N Engl J Med 2019
275
13

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
Junji Tsurutani, Hiroji Iwata, Ian Krop, Pasi A Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles Redfern, Kenji Tamura, Trisha M Wise-Draper,[...]. Cancer Discov 2020
91
14

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
Josep Tabernero, Paulo M Hoff, Lin Shen, Atsushi Ohtsu, Manish A Shah, Karen Cheng, Chunyan Song, Haiyan Wu, Jennifer Eng-Wong, Katherine Kim,[...]. Lancet Oncol 2018
169
12

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Peter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, Eric Van Cutsem, Jaffer A Ajani, Hugo Castro, Wasat Mansoor, Hyun Cheol Chung, Gyorgy Bodoky, Kohei Shitara,[...]. Lancet Oncol 2017
217
12

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Rashmi K Murthy, Sherene Loi, Alicia Okines, Elisavet Paplomata, Erika Hamilton, Sara A Hurvitz, Nancy U Lin, Virginia Borges, Vandana Abramson, Carey Anders,[...]. N Engl J Med 2020
358
12

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
José Baselga, Javier Cortés, Sung-Bae Kim, Seock-Ah Im, Roberto Hegg, Young-Hyuck Im, Laslo Roman, José Luiz Pedrini, Tadeusz Pienkowski, Adam Knott,[...]. N Engl J Med 2012
12


Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, Edmund A Rossi, Robert M Sharkey. Oncotarget 2015
156
11

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Udai Banerji, Carla M L van Herpen, Cristina Saura, Fiona Thistlethwaite, Simon Lord, Victor Moreno, Iain R Macpherson, Valentina Boni, Christian Rolfo, Elisabeth G E de Vries,[...]. Lancet Oncol 2019
111
11

Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads.
Takashi Nakada, Takeshi Masuda, Hiroyuki Naito, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Yusuke Ogitani, Junko Yamaguchi,[...]. Bioorg Med Chem Lett 2016
46
23

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
Gunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, Sibylle Loibl, Eleftherios P Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiss, Andres Redondo,[...]. N Engl J Med 2019
737
11

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
Jonathan E Rosenberg, Peter H O'Donnell, Arjun V Balar, Bradley A McGregor, Elisabeth I Heath, Evan Y Yu, Matthew D Galsky, Noah M Hahn, Elaina M Gartner, Juan M Pinelli,[...]. J Clin Oncol 2019
214
11

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
Alexander N Starodub, Allyson J Ocean, Manish A Shah, Michael J Guarino, Vincent J Picozzi, Linda T Vahdat, Sajeve S Thomas, Serengulam V Govindan, Pius P Maliakal, William A Wegener,[...]. Clin Cancer Res 2015
129
10

Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys.
Thomas M Cardillo, Serengulam V Govindan, Robert M Sharkey, Preeti Trisal, David M Goldenberg. Clin Cancer Res 2011
124
10

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Véronique Diéras, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E Krop, Kim Blackwell, Silke Hoersch, Jin Xu,[...]. Lancet Oncol 2017
248
10

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
J Randolph Hecht, Yung-Jue Bang, Shukui K Qin, Hyun C Chung, Jianming M Xu, Joon O Park, Krzysztof Jeziorski, Yaroslav Shparyk, Paulo M Hoff, Alberto Sobrero,[...]. J Clin Oncol 2016
336
10

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.
Taroh Satoh, Rui-Hua Xu, Hyun Cheol Chung, Guo-Ping Sun, Toshihiko Doi, Jian-Ming Xu, Akihito Tsuji, Yasushi Omuro, Jin Li, Jin-Wan Wang,[...]. J Clin Oncol 2014
383
10

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Charles E Geyer, John Forster, Deborah Lindquist, Stephen Chan, C Gilles Romieu, Tadeusz Pienkowski, Agnieszka Jagiello-Gruszfeld, John Crown, Arlene Chan, Bella Kaufman,[...]. N Engl J Med 2006
10

Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
Svetlana O Doronina, Brian E Toki, Michael Y Torgov, Brian A Mendelsohn, Charles G Cerveny, Dana F Chace, Ron L DeBlanc, R Patrick Gearing, Tim D Bovee, Clay B Siegall,[...]. Nat Biotechnol 2003
721
10

Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Pia M Challita-Eid, Daulet Satpayev, Peng Yang, Zili An, Karen Morrison, Yuriy Shostak, Arthur Raitano, Rossana Nadell, Wendy Liu, Dawn Ratay Lortie,[...]. Cancer Res 2016
158
10

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
Bob T Li, Ronglai Shen, Darren Buonocore, Zachary T Olah, Ai Ni, Michelle S Ginsberg, Gary A Ulaner, Michael Offin, Daniel Feldman, Todd Hembrough,[...]. J Clin Oncol 2018
196
9


Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
Ian E Krop, Sung-Bae Kim, Antonio González-Martín, Patricia M LoRusso, Jean-Marc Ferrero, Melanie Smitt, Ron Yu, Abraham C F Leung, Hans Wildiers. Lancet Oncol 2014
394
9

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer.
Gabriel Rinnerthaler, Simon Peter Gampenrieder, Richard Greil. Int J Mol Sci 2019
72
12

[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
Naoki Takegawa, Junji Tsurutani, Hisato Kawakami, Kimio Yonesaka, Ryoji Kato, Koji Haratani, Hidetoshi Hayashi, Masayuki Takeda, Yoshikane Nonagase, Osamu Maenishi,[...]. Int J Cancer 2019
30
30

SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer.
Django Sussman, Leia M Smith, Martha E Anderson, Steve Duniho, Joshua H Hunter, Heather Kostner, Jamie B Miyamoto, Albina Nesterova, Lori Westendorf, Heather A Van Epps,[...]. Mol Cancer Ther 2014
65
13

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
Aditya Bardia, Ingrid A Mayer, Jennifer R Diamond, Rebecca L Moroose, Steven J Isakoff, Alexander N Starodub, Nikita C Shah, Joyce O'Shaughnessy, Kevin Kalinsky, Michael Guarino,[...]. J Clin Oncol 2017
155
9

Antibody-Drug Conjugates: A Comprehensive Review.
Puregmaa Khongorzul, Cai Jia Ling, Farhan Ullah Khan, Awais Ullah Ihsan, Juan Zhang. Mol Cancer Res 2020
144
9

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Sandra M Swain, José Baselga, Sung-Bae Kim, Jungsil Ro, Vladimir Semiglazov, Mario Campone, Eva Ciruelos, Jean-Marc Ferrero, Andreas Schneeweiss, Sarah Heeson,[...]. N Engl J Med 2015
9

Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
Fu Li, Kim K Emmerton, Mechthild Jonas, Xinqun Zhang, Jamie B Miyamoto, Jocelyn R Setter, Nicole D Nicholas, Nicole M Okeley, Robert P Lyon, Dennis R Benjamin,[...]. Cancer Res 2016
120
9



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.